Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vericiguat in Indian Patients with HFrEF
NCT05658458Phase 4Completed
- Sponsor
- Bayer
- Start
- Dec 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vericiguat in heart failure with reduced ejection fraction (HFrEF), sponsored by Bayer. Started Dec 2022; status: completed.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05658458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05658458.